Embed Size (px)
Citation preview
liveworx.com # L I V E W O R X
INNOVATION JOURNEY: DESIGN ANYWHERE / BUILD ANYWHERE
Tria Hauglie – Boston Scientific Corporation Tom Hartmann - Accenture
# L I V E W O R X 2
ARE YOU IN THE RIGHT ROOM?
# L I V E W O R X 3
QUESTION 1
• Do you have all the product innovation you need?
# L I V E W O R X 4
QUESTION 2
Are you delivering
innovation as fast as your
market demands?
# L I V E W O R X 5
QUESTION 3
Are you providing product
knowledge efficiently to
everyone who needs it?
# L I V E W O R X 6
Bonsus
BONUS QUESTIONS
Do your senior executives
enthusiastically approve your budget
requests?
Does the organization
want your innovation
efforts?
# L I V E W O R X 7
AGENDA
1. Introductions and
Overview
3. Transforming
Product
Development
2. Our Innovation
Journey
4. Q&A
# L I V E W O R X 8
WHO WE ARE
IT Global Director, Boston Scientific
Office of IT – PMO, Processes, Value
Improvement, Strategic Sourcing,
Communications
• Solution Delivery Leadership; PLM,
Financial Systems, HR Systems
• Guest Lecture – University of
Minnesota - Carlson School of
Management
Based in Minneapolis, MN
Managing Director at Accenture
North America Technology Consulting – Connected
Product Lifecycle Lead
o 20+ years of Product Development and
Lifecycle experience
oBoston Scientific, Stryker, Merck Consumer
Care, Pfizer, P&G, Unilever, Mondelez, AB
InBev, WMS Gaming, Motorola, HP, Sun
Microsystems, Raytheon…
oBased in Chicago, IL
Tria Hauglie Tom Hartmann
# L I V E W O R X 9
Boston Scientific Corporation transformed their R&D and Quality organization to drive measurable business value through PLM strategy and technology in their journey to realize a “Design Anywhere / Build Anywhere” vision.
The session will focus on:
– Design Anywhere / Build Anywhere Journey
– How to build business adoption
– Business Case through value realization
– Delivery Excellence through Agile methodology
– Enabling new R&D and Quality business capabilities
INTRODUCTION
# L I V E W O R X 10
• Start organizational adoption from day 1 of the program
• Focus scope on measurable business value
• Deliver in an Agile manner
THREE THINGS TO TAKE AWAY
# L I V E W O R X 11
BOSTON SCIENTIFIC CORE BUSINESS
Interventional Cardiology technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders.
Cardiac Rhythm Management
solutions for treating irregular heart rhythms and heart failure, and protecting against sudden cardiac arrest.
Urology and Women’s Health solutions for treating urological and gynecological disorders like kidney and bladder stones, stress urinary incontinence, pelvic organ prolapse and excessive uterine bleeding.
Neuromodulation microelectronic implantable technologies for managing chronic neuropathic pain and neurological diseases.
Electrophysiology technologies, such as mapping catheters and radiofrequency energy for diagnosing and treating heart rhythm disorders.
Peripheral Intervention solutions for treating vascular system blockages in areas such as the carotid and renal arteries and the lower extremities.
Endoscopy technologies for diagnosing and treating diseases of the digestive system, airway and lungs.
# L I V E W O R X 12 12 # L I V E W O R X
ACCENTURE CONNECTED PRODUCT LIFECYCLE SERVICES
# L I V E W O R X 13
AGENDA
1. Introductions and
Overview
3. Transforming
Product
Development
2. Our Innovation
Journey
4. Q&A
# L I V E W O R X 14
RECENT PLM JOURNEY
• Multiple legacy PLM Systems: PDM,
Windchill 9, Athena
• Unsupported PLM Platforms
• Unstable to Microsoft upgrades, SAP
upgrades, any interfaces to PDM
FROM TO
• One consolidated PLM Solution
• Harmonization and Simplified R&D and
Quality processes
• 20,000+ users enabled on PTC Windchill
• 50% reduction in TCO over next 10 years
• $27M opportunity - Target 40% efficiency
improvement
# L I V E W O R X 15
AGENDA
1. Introductions and
Overview
3. Transforming
Product
Development
2. Our Innovation
Journey
4. Q&A
# L I V E W O R X 16
TRANSFORMATION STEPS
1. How to build business adoption
2. Business Case through value realization
3. Delivery Excellence through Agile methodology
4. Enabling new R&D and Quality business capabilities
# L I V E W O R X 17
PROJECT CHARTER SPONSOR MISALIGNMENT – NO CLEAR OBJECT
Problem Objective Current /
Future State
Benefit Funding Engagement Phases
Director Quality Program Mgmt
Director Quality
VP Quality Systems
Director Finance
VP R&D
VP Ops
Director R&D IT
VP IT
# L I V E W O R X 18
STEP 1- HOW TO BUILD BUSINESS ADOPTION VOICE OF CUSTOMER
International
Coyol, Costa Rica
Heredia, Costa Rica
St. Paul, MN
Maple Grove, MN
Quincy, MA
Marlborough, MA Spencer, IN
San Jose, CA
Fremont, CA
Valencia, CA
Clonmel
Cork
Galway
Dorado, Puerto Rico
Site Site Lead
AMS (Minnetonka & CA)
Bay Area
Cambridge
Clonmel
Coon Rapids
Cork
Coventry
Coyol
Dorado
Intl AMEA, Americas & Europe
Galway
Gurgaon
Heredia
Kerkrade
Lowell
Los Gatos
Maple Grove
Marlborough
Paris/Intl
Quincy
Spencer
St Paul
Valencia
Kerkrade
Coon Rapids, MN
Coventry, MA
# L I V E W O R X 19
STEP 2- BUSINESS CASE DEVELOPMENT SECURE FUNDING
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun
Build Business
Case
Create Charter Gain Approval
Validate Alignment
Base Charter
Condcut VoC
Establish Project Plan
ROM Plan
Strat
FY14 Funding
Key Lessons
Jul
• Educate team on creating business case • Establish process for documenting cost
savings • Accept all savings – big and small
• Establish detailed plan • Establish team processes • Get 3 estimates to finalize plan and
necessary funding
• Customer Voice • Use Customer Voice to Quantify Problem • Leverage Customer in project
• Educate Sponsors • Validate Alignment • Words Matter • Reference Charter
Utilize Charter as Base to Build Project Plan, Secure Funding
Valiate Plan
Aug Sep
Design
Review
• Identify funding needs early • Market, Market, Market • Tell the story
Methods and practices established for success
Secure
Funding
Gap Assessment
Detailed Plan
RFP
FY15 Funding
Logistics
Execute VoC
Summarize Value
Sell, Sell, Sell
Current State
Future State
Cost Saving Analysis
Sell Sell Sell
# L I V E W O R X 20
STEP 3 - DELIVERY EXCELLENCE THROUGH AGILE METHODOLOGY
Leading Practices:
• Clearly Defined Use Cases and Detailed
Requirements
• Leverage Real Business Data for Testing
(utilize Data Conversion Loads)
• Focus on data cleansing and enrichment
early and Test
• Focus on system integrations early
• Plan for early Design UAT with 1 or 2
Backlog Sprints
• Strong Change Control Process
• Strong executive stakeholders and
sponsors (making PLM a priority)
Hybrid Agile Methodology
# L I V E W O R X 21
VIP Platinum Award Key Results
STEP 4 - ENABLING NEW R&D AND QUALITY BUSINESS CAPABILITIES - GLOBAL DOCUMENT CONTROL VIP PLATINUM
Savings: $10.4 annual
Access Efficiency w/
Single Sign-on =
elimination of 300
hours/month & another
1,000 w/Release 2 users
Quicker Processing Time
= 1 hour quicker for each
change
Key Support • All Boston Scientific
Key Products • Procedures (R1- August 2015)
• Product Data (R2- 2016)
• Collaboration (R3 – 2016)
Key Technology • Windchill: Product Data
Management solution
Profile • Value of Production = % of all
savings allocated to each site based on current # of user licenses
Before
•Login each PDM access point
•Difficult environment for making
changes
• Inefficient navigation
•Non-standard methods to save a
search or frequently used
documents
•Manual data verification
After
Single Sign on eliminates logging
in
Simplified user interface
Retired systems
Improved search capabilities
Business rules perform systematic
data verification
Toolkit (s) Used
# L I V E W O R X 22
STEP 4 - ENABLING NEW R&D AND QUALITY BUSINESS CAPABILITIES
Fast Track Change Notice (CN) Creation
• If you need to route a Windchill Objects (DHF, DMR, Equipment) for approval, use the Fast Track CN.
• One or multiple objects can be routed on a Fast Track CN. The system will enforce approvers are specified based on the guiding SOP/WI(s) of the object(s) on the CN.
• This is a streamlined process in which any qualified person can create a Fast Track CN.
Savings: $5.6M annual
Streamlined process by which documents can be routed for approval
Before After
• Swift CR in PDM
• CR in PDM
• Managed Document in Windchill 9
• Concept Functionality in Windchill 9
• Fast Track CN in Windchill 10
Approvals:
• PDM – giant approval matrix
• Windchill 9 – system and procedure
enforced rules
Approvals of objects are driven by the
guiding SOP or WI, which are system
enforced
# L I V E W O R X 23
AGENDA
1. Introductions and
Overview
3. Transforming
Product Development
2. Our Innovation
Journey
4. Q&A
# L I V E W O R X 24
QUESTIONS
25 # L I V E W O R X
WE WANT YOUR FEEDBACK Please remember to complete
your evaluation by selecting
the session in your mobile app.
Survey
# L I V E W O R X 26
Safe Harbor:
This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,” “estimate,” “intend,” and similar words. These forward-looking statements are based on our beliefs, assumptions, and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that could cause actual results to differ materially from those expressed in forward-looking statements can be found in our latest Form 10-K and Form 10-Q under the heading “Risk Factors.” Participants are cautioned not to place undue reliance on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
For reconciliations of non-GAAP financial measures used in this presentation to the most directly comparable GAAP figures, please refer to the Investor Relations section of our website at www.bostonscientific.com.
Instructions for Use:
This corporate presentation may be used with internal and external audiences to provide a general overview of Boston Scientific. Typical audiences include recruiting professionals and partners/vendors. Talking points have been provided in the notes section. This presentation may not be altered or repurposed without written consent from Global Corporate Communications and the Corporate Legal and Regulatory departments. While all information incorporated is publicly available, we ask that you use discretion in the dissemination of electronic or printed versions of this presentation to limit exposure to competitive audiences.
SAFE HARBOR
